Company profile
Compass Therapeutics, Inc.
NASDAQ: CMPX · Healthcare · Biotechnology
#1166 of 1,422 Healthcare companies by revenuebottom-decile growth
EA Score
51DFH 63DQ 33GM —SS 48
v0.1 · 55/100 weight · provisional
↑ balance-sheet leverage, Altman-Z · ↓ revenue growth (YoY), disclosure history
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$66.5M
Employees
39
as of 2026-08-13
Market cap
$426.8M
as of 2026-08-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$66.5M-$66.5M2025
Operating income-$72.8M-$72.8M2025
Total assets$219.6M$219.6M2025
Liabilities$22.8M$22.8M2025
Equity$196.8M$196.8M2025
Revenue trend
FY2024 – FY2025 · USD
FY24
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Compass Therapeutics, Inc.’s revenue?
Compass Therapeutics, Inc. booked $0 in FY2025 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Nika Pharmaceuticals Inc.29DBenitec Biopharma Inc.47DLarimar Therapeutics, Inc.38DRocket Pharmaceuticals, Inc.53DPalisade Bio, Inc.71BSAB Biotherapeutics, Inc.52DNeighbors
Suffolk →Key facts
CEOThomas J. Schuetz
SectorHealthcare
IndustryBiotechnology
HeadquartersBoston, MA
ExchangeNASDAQ: CMPX
Employees39
IPO date2021-04-05
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.